---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-24-000062"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:03:05.250552+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q3 revenue up 2.8% to $649.7M; net income $653.2M on Sartorius gain

## Summary
- Net sales $649.7M, +2.8% YoY; currency-neutral +3.4%; Clinical Diagnostics grew 5.6% to $388.8M.
- Life Science segment sales $260.9M, -1.0% YoY, citing ongoing biotech/biopharma weakness.
- Income from operations fell to $64.5M from $90.9M; net income surged to $653.2M ($23.34 EPS) on Sartorius fair value change.
- Gross margin improved to 54.8% from 53.1% YoY; effective tax rate 24.2%.
- Appointed Jon DiVincenzo as President and COO; CEO cites gradual biopharma recovery and new leadership.

## SEC filing metadata
- accession: 0000012208-24-000062
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220824000062/0000012208-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220824000062/bio-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-24-000062
- JSON: https://secwatch.observer/filing/0000012208-24-000062.json
- Plain text: https://secwatch.observer/filing/0000012208-24-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.